RECOMMEND Platform Trial

Launched by AUSTRALIAN AND NEW ZEALAND INTENSIVE CARE RESEARCH CENTRE · Jul 25, 2024

Keywords

ClinConnect Summary

The RECOMMEND Platform Trial is a research study designed to improve care for patients on extracorporeal membrane oxygenation (ECMO), a treatment used in the intensive care unit (ICU) to help patients with severe breathing problems. The goal of the trial is to create better guidelines and evidence for ECMO care, so doctors can make more informed decisions based on the latest research. This trial will also allow researchers to test different treatment options at the same time, making it easier and faster to find out what works best for patients.

To participate in this trial, patients must be receiving ECMO and enrolled in a specific registry called the EXCEL Registry. Unfortunately, if a doctor believes that death is imminent for a patient or that participating in the trial may not be in the patient’s best interest, they will not be eligible. While the trial is not yet recruiting participants, it emphasizes the importance of patient preferences and aims to provide valuable insights to improve outcomes for those receiving ECMO care.

Gender

ALL

Eligibility criteria

• PLATFORM INCLUSION CRITERIA:
• • Patients receiving ECMO
• • Patients enrolled in the EXCEL Registry - NCT03793257
• PLATFORM EXCLUSION CRITERIA:
• • Treating clinician regards death as imminent and inevitable
• • Treating clinician determines it is not in the patient's best interests
• RBC TRANSFUSION DOMAIN INCLUSION CRITERIA:
• • • Aged 18 years or older
• RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA:
• • Contraindication to RBC transfusion (including known patient preference)
• • Limitations of care put in place either through patient wishes or the treating medical teams.
• • Participant has already received ECMO \>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery)
• • The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
• • The treating physician deems the study is not in the patient's best interest
• • The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
• • Actively listed for a solid organ transplant and has not yet received one
• • Suspected or confirmed to be pregnant
• • Previous ECMO treatment during the same hospital admission